Cushing's Syndrome in the Elderly

Abstract

Management of Cushing’s syndrome (CS) can be particularly challenging in older patients, compared with younger individuals, due to the lack of several clinical features associated with cortisol excess along with a greater burden of associated comorbidities. Moreover, the interpretation of diagnostic tests could be influenced by age-related physiological changes in cortisol secretion. While mortality is higher and quality of life is more impaired in the elderly with CS as compared with the younger, there is currently no agreement on the most effective therapeutic options in aged individuals, and safety data concerning medical treatment are scanty. In this review, we summarize the current knowledge about age-related differences in CS etiology, clinical presentation, treatment, and outcomes and describe the potential underlying mechanisms.

Keywords

Cushing’s syndrome - older patients - aging - hypercortisolism

Publikationsverlauf

Eingereicht: 05. Februar 2024
Eingereicht: 11. April 2024

Angenommen: 30. April 2024

Accepted Manuscript online:
02. Mai 2024

Artikel online veröffentlicht:
25. Juni 2024

• References

• 1 Valassi E. Clinical presentation and etiology of Cushing’s syndrome: Data from ERCUSYN. J Neuroendocrinol 2022; 34: e13114
• 2 Wengander S, Trimpou P, Papakokkinou E. et al. The incidence of endogenous Cushing’s syndrome in the modern era. Clin Endocrinol (Oxf) 2019; 91: 263-270
• 3 Rubinstein G, Osswald A, Hoster E. et al. Time to diagnosis in Cushing’s syndrome: A meta-analysis based on 5367 patients. J Clin Endocrinol Metab 2020; 105 dgz136
• 4 Braun LT, Riester A, Oßwald-Kopp A. et al. Toward a diagnostic score in Cushing’s syndrome. Front Endocrinol 2019; 10: 766
• 5 Kowal P, Dowd J. Definition of an older person. Proposed working definition of an older person in Africa for the MDS Project. Geneva: World Health Organization; 2001
• 6 Akirov A, Dery L, Fleseriu M. et al. Cushing’s syndrome in women: Age-related differences in etiology and clinical picture. Pituitary 2023; 26: 144-151
• 7 Ebbehoj A, Li D, Kaur RJ. et al. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: A population-based cohort study. Lancet Diabetes Endocrinol. 2020. 8. 894-902
• 8 Zavatta G, Vicennati V, Altieri P. et al. Mild autonomous cortisol secretion in adrenal incidentalomas and risk of fragility fractures: A large cross-sectional study. Eur J Endocrinol 2023; 188: 343-352
• 9 Amodru V, Ferriere A, Tabarin A. et al. Cushing’s syndrome in the elderly: Data from the European Registry on Cushing’s syndrome. Eur J Endocrinol 2023; 188: 395-406
• 10 Qiao N, Swearingen B, Tritos NA. Cushing’s disease in older patients: Presentation and outcome. Clin Endocrinol (Oxf) 2018; 89: 444-453
• 11 Storr HL, Isidori AM, Monson JP. et al. Prepubertal Cushing’s disease is more common in males, but there is no increase in severity at diagnosis. J Clin Endocrinol Metab 2004; 89: 3818-3820
• 12 Pecori Giraldi F, Cassarino MF, Sesta A. et al. Sexual dimorphism in cellular and molecular features in human ACTH-secreting pituitary adenomas. Cancers 2020; 12: 669
• 13 Young J, Haissaguerre M, Viera-Pinto O. et al. Management of endocrine disease: Cushing’s syndrome due to ectopic ACTH secretion: An expert operational opinion. Eur J Endocrinol 2020; 182: R29-R58
• 14 Kamp K, Alwani RA, Korpershoek E. et al. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors. Eur J Endocrinol 2016; 174: 271-280
• 15 Beuschlein F, Hammer GD. Ectopic pro-opiomelanocortin syndrome. Endocrinol Metab Clin North Am 2002; 31: 191-234
• 16 Hayes AR, Grossman AB. The ectopic adrenocorticotropic hormone syndrome. Endocrinol Metab Clin North Am 2018; 47: 409-425
• 17 Ilias I, Torpy DJ, Pacak K. et al. Cushing’s syndrome due to ectopic corticotropin secretion: Twenty years’ experience at the National Institutes of Health. J Clin Endocrinol Metab 2005; 90: 4955-4962
• 18 Rockall AG, Sohaib SA, Evans D. et al. Computed tomography assessment of fat distribution in male and female patients with Cushing’s syndrome. Eur J Endocrinol 2003; 149: 561-567
• 19 Ferraù F, Korbonits M. Metabolic comorbidities in Cushing’s syndrome. Eur J Endocrinol 2015; 173: M133-M157
• 20 Nowotny HF, Braun L, Vogel F. et al. 11-Oxygenated C19 steroids are the predominant androgens responsible for hyperandrogenemia in Cushing’s disease. Eur J Endocrinol 2022; 187: 663-673
• 21 Nanba AT, Rege J, Ren J. et al. 11-Oxygenated C19 steroids do not decline with age in women. J Clin Endocrinol Metab 2019; 104: 2615-2622
• 22 Liao YH, Chen SY, Chou SY. et al. Determination of chronological aging parameters in epidermal keratinocytes by in vivo harmonic generation microscopy. Biomed Opt Express 2013; 4: 77-88
• 23 Cruz-Jentoft AJ, Bahat G, Bauer J. et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16-31
• 24 Dardevet D, Sornet C, Taillandier D. et al. Sensitivity and protein turnover response to glucocorticoids are different in skeletal muscle from adult and old rats. Lack of regulation of the ubiquitin-proteasome proteolytic pathway in aging. J Clin Invest 1995; 96: 2113-2119
• 25 Rieu I, Sornet C, Grizard J. et al. Glucocorticoid excess induces a prolonged leucine resistance on muscle protein synthesis in old rats. Exp Gerontol 2004; 39: 1315-1321
• 26 Vogel F, Braun LT, Rubinstein G. et al. Persisting muscle dysfunction in Cushing’s syndrome despite biochemical remission. J Clin Endocrinol Metab 2020; 105: e4490-e4498
• 27 Cuthbertson DJ, Bell JA, Ng SY. et al. Dynapenic obesity and the risk of incident type 2 diabetes: The English Longitudinal Study of Ageing. Diabet Med J Br Diabet Assoc 2016; 33: 1052-1059
• 28 Vogel F, Braun L, Rubinstein G. et al. Patients with low IGF-I after curative surgery for Cushing’s syndrome have an adverse long-term outcome of hypercortisolism-induced myopathy. Eur J Endocrinol 2021; 184: 813-821
• 29 Zheng H, Wang Q, Cui Q. et al. The hypothalamic-pituitary-gonad axis in male Cushing’s disease before and after curative surgery. Endocrine 2022; 77: 357-362
• 30 Hassan-Smith ZK, Morgan SA, Sherlock M. et al. Gender-specific differences in skeletal muscle 11β-HSD1 expression across healthy aging. J Clin Endocrinol Metab 2015; 100: 2673-2681
• 31 Giuliodori A, Soudah E, Malouf J. et al. Evaluation of bone-related mechanical properties in female patients with long-term remission of Cushing’s syndrome using quantitative computed tomography–based finite element analysis. Eur J Endocrinol 2024; 190: 86-95
• 32 Riggs BL, Khosla S, Melton LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23: 279-302
• 33 Chin KY, Ima-Nirwana S, Mohamed IN. et al. Insulin-like growth factor-1 is a mediator of age-related decline of bone health status in men. Aging Male Off J Int Soc Study Aging Male 2014; 17: 102-106
• 34 Zhou H, Cooper MS, Seibel MJ. Endogenous glucocorticoids and bone. Bone Res 2013; 1: 107-119
• 35 Zilio M, Mazzai L, Sartori MT. et al. A venous thromboembolism risk assessment model for patients with Cushing’s syndrome. Endocrine 2016; 52: 322-332
• 36 Isand K, Feelders R, Brue T. et al. High prevalence of venous thrombotic events in Cushing’s syndrome: Data from ERCUSYN and details in relation to surgery. Eur J Endocrinol 2024; 190: 75-85
• 37 Piasecka M, Papakokkinou E, Valassi E. et al. Psychiatric and neurocognitive consequences of endogenous hypercortisolism. J Intern Med 2020; 288: 168-182
• 38 Anderson RM, Birnie AK, Koblesky NK. et al. Adrenocortical status predicts the degree of age-related deficits in prefrontal structural plasticity and working memory. J Neurosci 2014; 34: 8387-8397
• 39 Resmini E, Santos A, Gómez-Anson B. et al. Verbal and visual memory performance and hippocampal volumes, measured by 3-Tesla magnetic resonance imaging, in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2012; 97: 663-671
• 40 Papakokkinou E, Ragnarsson O. Functional brain alterations in Cushing’s syndrome. Front Endocrinol 2023; 14: 1163482
• 41 Hegeman JM, de Waal MWM, Comijs HC. et al. Depression in later life: A more somatic presentation?. J Affect Disord 2015; 170: 196-202
• 42 Lyu X, Zhang D, Pan H. et al. Machine learning models for differential diagnosis of Cushing’s disease and ectopic ACTH secretion syndrome. Endocrine 2023; 80: 639-646
• 43 Wudy SA, Hartmann MF, Remer T. Sexual dimorphism in cortisol secretion starts after age 10 in healthy children: Urinary cortisol metabolite excretion rates during growth. Am J Physiol Endocrinol Metab 2007; 293: E970-E976
• 44 Moffat SD, An Y, Resnick SM. et al Longitudinal change in cortisol levels across the adult life span. J Gerontol A Biol Sci Med Sci 20 2020; 75: 394-400
• 45 Purnell JQ, Brandon DD, Isabelle LM. et al. Association of 24-hour cortisol production rates, cortisol-binding globulin, and plasma-free cortisol levels with body composition, leptin levels, and aging in adult men and women. J Clin Endocrinol Metab 2004; 89: 281-287
• 46 Otte C, Hart S, Neylan TC. et al. A meta-analysis of cortisol response to challenge in human aging: Importance of gender. Psychoneuroendocrinology 2005; 30: 80-91
• 47 Mikneviciute G, Pulopulos MM, Allaert J. et al. Adult age differences in the psychophysiological response to acute stress. Psychoneuroendocrinology 2023; 153: 106111
• 48 Newell-Price J, Pivonello R, Tabarin A. et al. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease. Eur J Endocrinol 2020; 182: 207-217
• 49 Coelli S, Farias CB, Soares AA. et al Influence of age, gender and body mass index on late-night salivary cortisol in healthy adults. Clin Chem Lab Med CCLM 2017; 55 Available from: https://www.degruyter.com/document/
• 50 Thakur JD, Corlin A, Mallari RJ. et al. Complication avoidance protocols in endoscopic pituitary adenoma surgery: A retrospective cohort study in 514 patients. Pituitary 2021; 24: 930-942
• 51 Ünal M, Selek A, Sözen M. et al. Recurrent Cushing’s disease in adults: Predictors and long-term follow-up. Horm Metab Res Horm Stoffwechselforschung Horm Metab 2023; 55: 520-527
• 52 Liu Y, Liu X, Hong X. et al. Prediction of recurrence after transsphenoidal surgery for Cushing’s disease: The use of machine learning algorithms. Neuroendocrinology 2019; 108: 201-210
• 53 Pivonello R, Fleseriu M, Newell-Price J. et al. Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): A multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 2020; 8: 748-761
• 54 Gadelha M, Bex M, Feelders RA. et al. Randomized trial of osilodrostat for the treatment of Cushing disease. J Clin Endocrinol Metab 2022; 107: e2882-e2895
• 55 Berwaerts JJ, Verhelst JA, Verhaert GC. et al. Corticotropin-dependent Cushing’s syndrome in older people: Presentation of five cases and therapeutical use of ketoconazole. J Am Geriatr Soc 1998; 46: 880-884
• 56 Castinetti F, Guignat L, Giraud P. et al. Ketoconazole in Cushing’s disease: Is it worth a try?. J Clin Endocrinol Metab 2014; 99: 1623-1630
• 57 Daniel E, Aylwin S, Mustafa O. et al. Effectiveness of metyrapone in treating Cushing’s syndrome: A retrospective multicenter study in 195 patients. J Clin Endocrinol Metab 2015; 100: 4146-4154
• 58 Carroll TB, Peppard WJ, Herrmann DJ. et al. Continuous etomidate infusion for the management of severe Cushing syndrome: Validation of a standard protocol. J Endocr Soc 2019; 3: 1-12
• 59 Baudry C, Coste J, Bou Khalil R. et al. Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center. Eur J Endocrinol 2012; 167: 473-481
• 60 Petersenn S, Salgado LR, Schopohl J. et al. Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. Endocrine 2017; 57: 156-165
• 61 Castinetti F, Brue T, Ragnarsson O. Radiotherapy as a tool for the treatment of Cushing’s disease. Eur J Endocrinol 2019; 180: D9-D18
• 62 Mehta GU, Ding D, Patibandla MR. et al. Stereotactic radiosurgery for Cushing disease: Results of an international, multicenter study. J Clin Endocrinol Metab 2017; 102: 4284-4291
• 63 Ntali G, Asimakopoulou A, Siamatras T. et al. Mortality in Cushing’s syndrome: Systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 2013; 169: 715-723
• 64 Yaneva M, Kalinov K, Zacharieva S. Mortality in Cushing’s syndrome: Data from 386 patients from a single tertiary referral center. Eur J Endocrinol 2013; 169: 621-627
• 65 Lambert JK, Goldberg L, Fayngold S. et al. Predictors of mortality and long-term outcomes in treated Cushing’s disease: A study of 346 patients. J Clin Endocrinol Metab 2013; 98: 1022-1030
• 66 Valassi E, Tabarin A, Brue T. et al. High mortality within 90 days of diagnosis in patients with Cushing’s syndrome: Results from the ERCUSYN registry. Eur J Endocrinol 2019; 181: 461-472
• 67 Isidori AM, Kaltsas GA, Pozza C. et al. The ectopic adrenocorticotropin syndrome: Clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 2006; 91: 371-377
• 68 Santos A, Resmini E, Martínez Momblán MA. et al Quality of life in patients with Cushing’s disease. Front Endocrinol 2019; 10: 862 Available from: https://www.frontiersin.org/article/10.3389/fendo.2019.00862/full
• 69 Milian M, Honegger J, Teufel P. et al. Tuebingen CD-25 is a sensitive tool to investigate health-related quality of life in Cushing’s disease patients in the course of the disease. Neuroendocrinology 2013; 98: 188-199
• 70 Rakovec M, Zhu W, Khalafallah AM. et al. Patient reported outcomes and treatment satisfaction in patients with Cushing syndrome. Endocrine 2023; 79: 161-170
• 71 Gruber HJ, Semeraro MD, Renner W. et al. Telomeres and age-related diseases. Biomedicines 2021; 9: 1335
• 72 Calado RT, Young NS. Telomere diseases. N Engl J Med 2009; 361: 2353-2365
• 73 Simon NM, Smoller JW, McNamara KL. et al. Telomere shortening and mood disorders: Preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry 2006; 60: 432-435
• 74 Daubenmier J, Lin J, Blackburn E. et al. Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study. Psychoneuroendocrinology 2012; 37: 917-928
• 75 Choi J, Fauce SR, Effros RB. Reduced telomerase activity in human T lymphocytes exposed to cortisol. Brain Behav Immun 2008; 22: 600-605
• 76 Aulinas A, Ramírez MJ, Barahona MJ. et al. Telomere length analysis in Cushing’s syndrome. Eur J Endocrinol 2014; 171: 21-29